Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Can-Fite BioPharma Ltd. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 11 | 9 | −2 |
| SharesConverted for a 1-for-10 split | 42.8K | 368.4K | +325.7K (+761.3%) |
| Value | $262.2K | $843.5K | +$581.3K (+221.7%) |
New holders (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 330,000 | $755.7K | 0.02% |
| JPMorgan Chase & Co | 100 | $0 | 0.00% |
Sold out (4)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Susquehanna International Group, LLP | 32,739 | $20.1K |
| Two Sigma Securities, LLC | 26,985 | $16.5K |
| Stifel Financial Corp | 12,000 | $7.36K |
| BNP Paribas Arbitrage, SA | 400 | $245 |